We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+57.35%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.79B
AUM Growth
+$267M
Cap. Flow
-$147M
Cap. Flow %
-8.23%
Top 10 Hldgs %
60.02%
Holding
83
New
11
Increased
14
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$33.6M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$26.3M
3
CBAY
Cymabay Therapeutics
CBAY
+$23.5M
4
PCVX icon
Vaxcyte
PCVX
+$18.5M
5
EYPT icon
EyePoint Inc
EYPT
+$18.2M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$178M
2
PLRX icon
Pliant Therapeutics
PLRX
+$38.4M
3
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$26M
4
ETNB
89bio
ETNB
+$25.5M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$22.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.17%
2 Financials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
51
ALX Oncology
ALXO
$284M
$4.6M 0.26%
612,079
– –
APLS
52
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$3.55M 0.2%
+39,000
New +$3.36M
BCAB icon
53
BioAtla
BCAB
$5.53M
$3.54M 0.2%
23,622
– –
CNTA
54
DELISTED
Centessa Pharmaceuticals
CNTA
$3.48M 0.19%
561,600
– –
CYPH
55
Cypherpunk Technologies Inc
CYPH
$71.7M
$3.36M 0.19%
1,073,046
+924,895
+624% +$4.64M
OCUL icon
56
Ocular Therapeutix
OCUL
$1.92B
$3.33M 0.19%
+645,000
New +$3.84M
GRNA
57
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
$2.74M 0.15%
9,188,659
– –
DMRA
58
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$2.57M 0.14%
40,810
– –
BHVN icon
59
Biohaven
BHVN
$2.17B
$1.96M 0.11%
81,963
– –
AUTL
60
Autolus Therapeutics
AUTL
$532M
$933K 0.05%
392,167
– –
LENZ
61
LENZ Therapeutics
LENZ
$164M
$519K 0.03%
28,507
– –
HARP
62
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$384K 0.02%
54,060
– –
BCEL
63
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$313K 0.02%
319,057
– –
ORTX
64
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$134K 0.01%
25,664
– –
ANNX icon
65
Annexon
ANNX
$918M
– –
-1,250,000
Closed -$4.81M
CMMB
66
Chemomab Therapeutics
CMMB
$13.2M
– –
-72,042
Closed -$458K
CYTK icon
67
Cytokinetics
CYTK
$11B
– –
-296,000
Closed -$10.4M
ELDN icon
68
Eledon Pharmaceuticals
ELDN
$267M
– –
-1,217,882
Closed -$2.87M
ELEV
69
DELISTED
Elevation Oncology
ELEV
– –
-1,952,032
Closed -$3.71M
FULC icon
70
Fulcrum Therapeutics
FULC
$288M
– –
-1,081,490
Closed -$3.08M
GLUE icon
71
Monte Rosa Therapeutics
GLUE
$1.33B
– –
-2,893,717
Closed -$22.5M
PLRX icon
72
Pliant Therapeutics
PLRX
$65M
– –
-1,444,000
Closed -$38.4M
PRME icon
73
Prime Medicine
PRME
$533M
– –
-734,350
Closed -$9.03M
PYXS icon
74
Pyxis Oncology
PYXS
$238M
– –
-272,537
Closed -$1.09M
TNGX icon
75
Tango Therapeutics
TNGX
$4.72B
– –
-4,116,949
Closed -$16.3M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Cormorant Asset Management held 83 positions worth $1.79B, up 18% from $1.52B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Cormorant Asset Management withdrew a net $147M in Q2 2023, closing 19 positions and reducing 6 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $178M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Zentalis Pharmaceuticals worth $30.9M.

  • Cormorant Asset Management's largest Q2 2023 buy was Zentalis Pharmaceuticals: 1,095,000 shares worth $30.9M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q2 2023, an estimated $33.6M increase.
  • Cormorant Asset Management's biggest Q2 2023 reduction was 89bio, cutting an estimated $25.5M.
  • Cormorant Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $178M.
  • Cormorant Asset Management's ten largest holdings make up 60% of its $1.79B portfolio in Q2 2023.
  • Cormorant Asset Management opened 11 new positions and closed 19 in Q2 2023.
  • Cormorant Asset Management's portfolio value rose 18% quarter-over-quarter to $1.79B.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.